专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010088548A1 POSTERIOR SEGMENT DRUG DELIVERY 审中-公开
标题翻译：前期部分药物递送
公开(公告)号：WO2010088548A1
公开(公告)日：2010-08-05
申请号：PCT/US2010/022631
申请日：2010-01-29
申请人： FORSIGHT LABS, LLC , DE JUAN, JR., Eugene , ALSTER, Yair , CHAMOW, Steven M. , COGAN FARINAS, Kathleen , GIFFORD III, Hanson S. , MACFARLANE, K. Angela , REICH, Cary J. , BARRETT, Michael , CAMPBELL, Randolph E. , GEORGE, Robert , SUTTON, Douglas
发明人： DE JUAN, JR., Eugene , ALSTER, Yair , CHAMOW, Steven M. , COGAN FARINAS, Kathleen , GIFFORD III, Hanson S. , MACFARLANE, K. Angela , REICH, Cary J. , BARRETT, Michael , CAMPBELL, Randolph E. , GEORGE, Robert , SUTTON, Douglas
IPC分类号： A61M35/00
CPC分类号： G01N33/558 , A61F9/0017 , A61K9/0048 , A61K9/0051 , A61K31/57 , A61K31/573 , A61K31/58 , A61K38/385 , A61K47/32 , A61K47/34 , A61K47/38 , A61K2039/505 , C07K16/22 , C07K2317/24 , C07K2317/55 , Y10T29/49826
摘要： A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The therapeutic device may comprise a retention structure and a reservoir, such that the device can be delivered from a lumen of a delivery device. The therapeutic device may comprises a port to inject therapeutic agent into the device when implanted in the patient.
摘要翻译：用于释放治疗剂的治疗装置包括联接到包括储存器的容器的多孔结构。储存器包括体积大小，当耦合到多孔结构并且植入患者体内时，释放治疗剂量的治疗剂延长的时间。治疗装置可以包括保持结构和储存器，使得该装置可以从输送装置的内腔递送。治疗装置可以包括当植入患者时将治疗剂注射到装置中的端口。

2. 发明申请

WO2007115261A2 DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM 审中-公开
标题翻译：用于NASOLACRIMAL系统的药物递送方法，结构和组合物
公开(公告)号：WO2007115261A2
公开(公告)日：2007-10-11
申请号：PCT/US2007/065792
申请日：2007-04-02
申请人： FORSIGHT LABS, LLC , DE JUAN, JR., Eugene , REICH, Cary , BOYD, Stephen , GIFFORD, Hanson, S. , DEEM, Mark
发明人： DE JUAN, JR., Eugene , REICH, Cary , BOYD, Stephen , GIFFORD, Hanson, S. , DEEM, Mark
IPC分类号： A61K31/215 , A61K38/13 , A61P27/02 , A61P27/06 , A61F2/02
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
摘要翻译：用于插入患者的泪点的植入物包括主体。主体具有远端，近端和它们之间的轴线。身体的远端可通过泪点向远端插入到小管腔内。身体包含药剂基质药物核心内的治疗剂。试剂基质暴露于泪液能够在持续的时间内有效的治疗剂释放到泪液中。身体具有设置在药剂基质上的护套以抑制药剂远离近端的释放。身体还具有被配置为接合腔壁组织的外表面，以便当设置在其中时阻止排出。在具体实施方案中，试剂基质包含非生物可吸收聚合物，例如与该试剂的非均匀混合物的硅氧烷。

3. 发明申请

WO2007115259A2 NASOLACRIMAL DRAINAGE SYSTEM IMPLANTS FOR DRUG THERAPY 审中-公开
标题翻译：用于药物治疗的NASOLACRIMAL排水系统植入物
公开(公告)号：WO2007115259A2
公开(公告)日：2007-10-11
申请号：PCT/US2007/065789
申请日：2007-04-02
申请人： FORSIGHT LABS, LLC , DE JUAN, JR., Eugene , BOYD, Stephen , REICH, Cary , RAPACKI, Alan , GIFFORD, Hanson, S. , DEEM, Mark
发明人： DE JUAN, JR., Eugene , BOYD, Stephen , REICH, Cary , RAPACKI, Alan , GIFFORD, Hanson, S. , DEEM, Mark
IPC分类号： A61K31/215 , A61K38/13 , A61P27/02 , A61P27/06 , A61F2/02
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/0026 , A61F9/00772 , A61F9/00781 , A61F2220/0008 , A61F2250/0067 , A61F2250/0087 , A61K9/00 , A61K9/0017 , A61K9/06 , A61K31/215 , A61K31/216 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/573 , A61K47/34 , A61L31/16
摘要： Implant devices, systems and methods for insertion into a punctum of a patient optionally comprises a drug core and a sheath body disposed over the drug core. The drug core includes a therapeutic agent deliverable into the eye, and the sheath defines at least one exposed surface of the drug core. The exposed surface(s) of the drug core may contact a tear or tear film fluid and release the therapeutic agent at therapeutic levels over a sustained period when the implant is implanted for use. The implant may include a retention element to retain the drug core and sheath body near the punctum, optionally comprising a shape memory alloy that can resiliently expand. An occlusive element may be attached to the retention element to at least partially occlude tear flow through the canalicular lumen.
摘要翻译：用于插入患者泪点的植入装置，系统和方法可任选地包括药物核心和设置在药物核心上方的鞘体。药物核心包括可递送到眼睛中的治疗剂，护套限定药物核心的至少一个暴露表面。药物核心的暴露表面可以接触泪液或泪膜流体，并且当植入物植入使用时在持续的时间内以治疗水平释放治疗剂。植入物可以包括保持元件，以将药物核心和鞘体保持在泪点附近，任选地包括可弹性膨胀的形状记忆合金。闭塞元件可以连接到保持元件以至少部分地封闭穿过小管腔的泪液流动。

4. 发明申请

WO2008083118A1 DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS 审中-公开
标题翻译：用于抑制光学缺陷的药物递送植入物
公开(公告)号：WO2008083118A1
公开(公告)日：2008-07-10
申请号：PCT/US2007/088701
申请日：2007-12-21
申请人： QLT PLUG DELIVERY, INC. , DE JUAN, JR., Eugene , BOYD, Stephen , REICH, Cary
发明人： DE JUAN, JR., Eugene , BOYD, Stephen , REICH, Cary
IPC分类号： A61F2/14 , A61M31/00 , A61M35/00 , A61B18/18
CPC分类号： A61F9/0017 , A61F9/00772 , A61F9/00781 , A61K9/0051
摘要： An implant for use with an eye comprises an implantable structure and a therapeutic agent. The therapeutic agent is deliverable from the structure into the eye so as to therapeutically effect and/or stabilize a refractive property of the eye. In many embodiments, the refractive property of the eye may comprise at least one of myopia, hyperopia or astigmatism. The therapeutic agent can comprise a composition that therapeutically effects or stabilizes the refractive property of the eye. The therapeutic agent may comprise at least one of a mydriatic or a cycloplegic drug. For example, the therapeutic agent may include a cycloplegic that comprises at least one of atropine, cyclopentolate, succinylcholine, homatropine, scopolamine, or tropicamide. In many embodiments, a retention element can be attached to the structure to retain the structure along a natural tissue surface.
摘要翻译：用于眼睛的植入物包括可植入结构和治疗剂。治疗剂可以从结构输送到眼睛中，以便治疗影响和/或稳定眼睛的折射性质。在许多实施例中，眼睛的折射特性可以包括近视，远视或散光中的至少一种。治疗剂可以包含治疗影响或稳定眼睛的折射性质的组合物。治疗剂可以包括散瞳药或痉挛药物中的至少一种。例如，治疗剂可以包括睫状肌麻痹症，其包括阿托品，环戊二酸酯，琥珀酰胆碱，同质素，东莨菪碱或托品酰胺中的至少一种。在许多实施例中，保持元件可以附接到结构以沿着天然组织表面保持结构。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式